Publications

Publications and posters

Click on the headings below to see further information regarding publications from the experts here at CEAC. In the majority of instances this includes publications in their entirity, as well as posters and other materials, on a range of topics which are relevant to our overall aims. 

For more information about any of our publications, please contact us.

CEAC Publications

  • Application of a High Throuput Method of Biomarker Discovery to Improvement of the EarlyCDT-Lung Test. Macdonald IK, Murray A, Healey G, Parsy-Kowalska C, Allen J, Chapman CJ, Sewell H, Robertson JFR. PLoS One. 2012;7(12):e51002.

    This is a practical example of the value of investing resources to develop a HTP technology. Such technology has contributed to improvement in the clinical utility of the EarlyCDT-Lung test, and so further aiding the early detection of lung cancer.
  • Development and Validation of a High Throuput System for Discovery of Antigens for Autoantibody Detection. Macdonald IK, Murray A, Allen J, Parsy-Kowalska C, Healey G, Chapman CJ, Sewell H, Robertson JFR. PLoS One 2012 7(7): e40759. doi:10.1371/journal.pone.0070759.

    Publication which detailed the technical development of a high throughput stategy to identify new antigens to add to the EarlyCDT-Lung panel, and to assist in the development of new panels for other cancers.
  • EarlyCDT-Lung test: improved clinical utility through additional autoantibody assays. Chapman CJ, Healey G, Murray A, Boyle P, Robertson C, Peek LJ, Allen J, Thorpe AJ, Hamilton-Fairley G, Parsy-Kowalska C, Macdonald I, Robertson J. Tumor Biol.201;33(5):1319-26. PMID 22492236.

    This publication describes the improvement of the EarlyCDT-Lung test, by changing from a panel of six to a panel of seven autoantibody assays. Analysis of these assays in an at-risk population of 1612 prospective individuals, confirmed the improvement and utility of the test in a clinical setting.
  • EarlyCDT-Lung: an Immuno-biomarker Test as an Aid to Early Detection of Lung Cancer. Lam S, Boyle P, Healey G, Maddison P, Peek L, Murray A, Chapman CJ, Allen J, Wood WC, Sewell HF, Robertson JFR. Cancer Prev Res;2011 4 (7) 1126-1134.

    Four additional studies of lung cancer (across all stages) (n=573) versus matched controls (n=793) using the EarlyCDT-Lung test. Showed good cancer : control discrimination. There were more matched controls than patients with lung cancer since matching for some studies involved ‘double matching’ – ie a lung cancer patient was matched to one control from Europe and one from the USA.
  • Immuno-biomarkers in small cell lung cancer: Potential early cancer signals. Chapman CJ, Thorpe AJ, Murray A, Parsy-Kowalska C, Allen J, Stafford K, Chauhan A, Kite T, Robertson J. Clin. Cancer Res. 2011 17(6): 1474-1480.

    A large series of small cell lung cancer (n=242) from a single centre compared to a similar number of controls matched by age, gender and smoking history. Confirmed good cancer : control discrimination and showed the autoantibody signal could be detected even in patients with stage 1A disease.
  • Clinical Validation of an Autoantibody Test for Lung Cancer. Boyle P, Chapman CJ, Holdenrieder S, Murray A, Robertson C, Wood WC, Maddison P, Healey G, Fairley GH, Barnes AC, Robertson JF. Ann Oncol. 2011 Feb;22(2):383-9. Epub 2010 Jul 30.

    Publication of three separate datasets which comprised Training and Validation datasets which led to the launch of the EarlyCDT-Lung test. In total these studies involved 1,398 samples, 655 from patients with lung cancer (across all stages), 655 matched controls and 88 patients with benign lung lesions.
  • Technical validation of an autoantibody test for lung cancer. Murray A, Chapman, CJ, Healey G, Peek LJ, Parsons G, Baldwin D, Barnes A, Sewell HF, Fritsche HA, Robertson JF. Ann Oncol. 2010 21(8): 1687-93. Epub 2010 Feb 2.

    Publication which detailed the technical validation of the EarlyCDT-Lung test assay – eg reproducibility, precision and accuracy.
  • Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer. Maurizio CI, YU Y, Mirandola L, Jenkins MR, Chapman C, Cannon M, Cobos E, Kast WM. PloS one. 2010 5(5), e10471.
  • Autoimmunity to SOX2, clinical phenotype and survival in patients with small-cell lung cancer. Maddison P, Thorpe A, Silcocks P, Robertson JFR, Chapman CJ. Lung Cancer. 2010 DOI: 10.1016/j.lungcan.2010.03.002.

    Report looked at whether or not the presence of SOX2 autoantibodies were associated with clinical parameters or correlated with patient prognosis. SOX2 autoantibodies were not an independent prognostic factor in lung cancer.
  • A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression. ABD Hamid UM, Royle L, Saldova R, Radcliffe CM, Harvey DJ, Storr SJ, Pardo M, Antrobus R, Chapman CJ, Zitzmann N, Robertson JF, Dwek RA, Rudd PM. Glycobiology. 2008 18(12): 1105-18.

    This publication was part of a collaboration with The University of Oxford looking at glycosylation pattern(s) in patients with breast cancer compared to controls. Specific changes due to breast cancer were identified.
  • Lung cancer – can autoantibodies provide an aid to diagnosis? Woodard, KW, Chapman CJ. Expert Opin. Med. Diagn. 2008 2(8).

    A review article.
  • The O-linked glycosylation of secretory/shed MUC1 from an advanced breast cancer patient's serum. Storr SJ, Royle L, Chapman CJ, Hamid UM, Robertson JF, Murray A, Dwek RA, Rudd PM. Glycobiology. 2008 18(6): 456-62.

    This publication came from a research collaboration with The University of Oxford looking at o-glycosylation pattern(s) in patients with breast cancer compared to controls. This showed some specific changes due to breast cancer.
  • Autoantibodies in Lung Cancer - possibilities for early detection and subsequent cure. Chapman CJ, Murray A, McElveen JE et al. Thorax 2008; 63: 228-233.

    Our first publication on lung cancer showing autoantibodies were present in patients with early stage (stage 1 & 2) lung cancer. The sensitivity was higher than the commercial test subsequently launched which highlights the difference between a research assay and a fully validated commercial test.
  • Two-step method to isolate target recombinant protein from co-purified bacterial contaminant SlyD after immobilised metal affinity chromatography. Parsy CB, Chapman CJ, Barnes AC, Robertson JFR, Murray A. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jun 15 853(1-2):314-319.

    Technical paper describing how to purify out a protein of interest from a bacterial contaminant protein which in some cases could make up half the protein produced by the E. coli bacteria.
  • Serum EGFR and HER-2 Expression in Primary and Metasaic Breast Cancer. Asgeirsson KS, Agrawal, A, Allen C, Hitch, A Ellis, IO Chapman CJ, Cheung, KL and Robertson JFR. Breast Cancer Res. 2007 9(6).

    Reported the measurement of the EGFR and HER2 antigens which are shed into the blood in patients with early and late stage breast cancer. HER2 results were in keeping with other published data but EGFR results were somewhat counter-intuitive.
  • Autoantibodies in breast cancer: their use as an aid to early diagnosis. Chapman C, Murray A, Chakrabarti J Thorpe A, Woolston C, Sahin U, Barnes A, Robertson J. Ann Oncol 2007; 18: 868873.

    Reported the presence of autoantibodies in primary breast cancer, including both early stage disease (Stage 1 & 2) and also pre-invasive breast cancer called ductal carcinoma in-situ.  
  • Use of autoantibodies in breast cancer screening and diagnosis. Storr SJ, Chakrabarti J, Barnes A, Murray A, Chapman CJ, Robertson JF. Expert Rev Anticancer Ther. 2006 6(8):1215-23.

    A review article. 
 

Peer reviewed oral presentation

  • Autoantibodies in Oncology – presence and use for early disease identification. C Chapman. XIII International Symposium on Biology and Clinical usefulness of tumor markers - Barcelona 2011
  • Autoantibodies in Lung Cancer and their use in Early Cancer Detection. C Chapman. ISOBM 2011 Florence
  • Autoantibodies in Oncology – an overview CJ Chapman. ISOBM 2010 Munich
  • Antigen positivity in the EarlyCDT-LungTM test by stage and histological subtype of lung cancer. P Boyle, S Lam, P Maddison, WC Wood, LJ Peek, A Murray, CJ Chapman, G Healey & JFR Robertson. Chest 2010; 138(4). Chest October 1, 2010 138:4 MeetingAbstracts 727A; doi:10.1378/chest.1050
  • The Presence of Autoantibodies to Tumour-Associated Antigens can Predate Clinical Diagnosis of Lung Cancer (CHEST 2010) C Chapman, J Robertson, A Murray, M Titulaer, B Lang, A Thorpe, G Paul, J Verschuuren, P Madisson. Chest October 1, 2010 138:4 MeetingAbstracts 775A; doi:10.1378/chest.10476
  • Autoantibody Detection of Cancer - the next step in earlier detection? C Chapman. ENASCO 2009
  • AUTOANTIBODIES IN CANCER - Autoantibodies to Annexins & Cytokeratins in Breast Cancer. K Woodard, JFR Robertson, A Murray, C Chapman. ISOBM 2007 Published in Tumor Biology 2007
 

Peer review poster presentations 2011

  • Cost-Effectiveness of Screening Older Adult Smokers for Lung Cancer with an Autoantibody Test (AABT). D. Weycker, P. Boyle, A. Lopez, J. R. Jett, F. Detterbeck, T. C. Kennedy, D. L. Miller, H. Fritsche, W. C. Wood, G.Hamilton-Fairley, J. F. Robertson, J. Edelsberg. Am J Respir Crit Care Med 183;2011: Am J Respir Crit Care Med 183;2011:A2937
  • EarlyCDT-Lung: A newly marketed blood test to aid the early detection of lung cancer in high-risk patients – enhances the positive predictive power of computed tomography. R Kucera, DW West. Am J Respir Crit Care Med 183;2011:
  • Demonstration of the Specificity of human autoantibody responses to tumor associated antigens. A Murray, S Storr, L Bottomley, J McElveen, C Parsy-Kowalska, C Chapman, J Robertson. Am J Respir Crit Care Med 183;2011:A4388
  • Mesothlioma and tumor-associated autoantibodies. C Chapman, AJ Thorpe, JFR Robertson, K Hollevoet, J van Meerbeeck, A Murray, CB Parsy-Kowalska, LJ Peek. Am J Respir Crit Care Med 183;2011:A5838
  • Serum autoantibodies to breast cancer associated antigens reflect tumor biology: an opportunity for early detection & prevention? Eiermann W, Jackson L, Murray A, Chapman CJ, Peek LJ, Widschwendter P, Allen J, Healey G, Robertson JFR SABS December 2011
  • Autoantibodies in Ovarian Cancer. Alhudiri IM, A Murray, K Williamson, D Nunns, TJ O’Brien, JF Robertson, CJ Chapman ISOBM 2011. Published in Tumor Biology
  • Autoantibodies to p53 can Predate a Clinical Diagnosis of Ovarian Cancer - A Case Report. Chapman C, Robertson J, Murray A, Maddison P. ISOBM 2011. Published in Tumor Biology
  • Autoantibodies as Immunobiomarkers in Lung Cancer and their use in Early Cancer Detection. CChapman, G Healey, A Murray, L Peek, P Boyle, G Hamilton-Fairley, J Robertson CRI – New York 2011
 

Peer review poster presentations 2010

 

Pre-2010

  • INVESTIGATION OF THE HUMORAL IMMUNE RESPONSE TO THE TUMOUR ASSOCIATED ANTIGEN, PSA, IN BREAST CANCER. Fulker M, Robertson JFR and Chapman CJ. ISOBM 2007 Published in Tumor Biology
  • Autoantibodies in Early Breast Cancer. CHAPMAN,C., MURRAY,A., MCELVEEN,J., CHAKRABARTI,J., ALLEN,C., WOOLSTON,C., BARNES,A., SAHIN,U., ELLIS,I. and ROBERTSON,J.F.R., 2006.. Tumor Biology, 27(Suppl 2), 57.
  • Autoantibodies in lung cancer. CHAPMAN,C., MURRAY,A., MCELVEEN,J., SAHIN,U., LUXEMBURGER,U., TURECI,O., WIEWRODT,R., BARNES,A. and ROBERTSON,J., 2006.. Tumor Biology, 27(Suppl 1), 41. 
  • Serum MUC1 O-glycans from cancer patients contain the Sialyl Tn antigen. STEPHENSON,S.S., ROYLE,L.R., DWEK,R., ROBERTSON,J., BARNES,A., CHAPMAN,C. and RUDD,P., 2006.. Tumor Biology, 27(Suppl 1), 63.
  • Serum vs Plasma in autoantibody detection. ELISA. WOOLSTON,C., MURRAY,A., ROBERTSON,J.F.R. and CHAPMAN,C.J., 2006. Tumor Biology, 27(Suppl 2), 37.
  • Comparison of the autoantibody reactivity of the extracellular and intracellular domains of the tumour antigen HER-2 in breast cancer diagnosis. WOOLSTON,C.M., O’CONNELL,S., MURRAY,A., ROBERTSON, J.F.R. and CHAPMAN,C.J., 2006.. Tumor Biology, 27(Suppl 2), 58.
  • Human autoantibodies to CA125. ALLEN,C., ROBERTSON,J., MURRAY,A. and CHAPMAN,C., 2006. Tumor Biology, 27(Suppl 1), 69.